Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
13.03.2017 22:00:00

Nobilis Health Announces Completion of Acquisition of Hamilton Vein Center

HOUSTON, March 13, 2017 /PRNewswire/ -- Nobilis Health Corp. (NYSE MKT: HLTH) ("Nobilis" or the "Company") today announced that it has closed its previously announced acquisition of Hamilton Vein Center.

"Hamilton Vein Center not only increases our in-network patient volume mix to over 60%, but its six facilities enhance our network of physicians, allowing Nobilis to generate additional surgical case volume and revenue while maintaining its commitment to high quality, concierge health care service patient experiences.  The Hamilton Vein brand is a tremendous addition to our network.  We look forward to marketing that brand and expanding our Clarity vascular brand to Austin and San Antonio, new markets for us, while driving additional volume to our Houston facilities," said Kenneth Efird, President of Nobilis.

The company acquired Hamilton for approximately $13.3 million, comprised of $8.3 million in cash and $5.0 million in the form of a convertible note. The note is convertible to cash or stock at the Company's election, and is payable in two equal installments over a two-year period.

About Nobilis Health Corp.
Nobilis (www.NobilisHealth.com) is a full-service healthcare development and management company, with 25 locations in seven states, including 4 hospitals, 10 ASCs and 11 clinics. In addition, Nobilis partners with an additional 38 facilities across the country. Marketing nine independent brands, Nobilis deploys a unique patient acquisition strategy driven by proprietary direct-to-consumer marketing technology, focusing on a specified set of procedures that are performed at our centers by local physicians.

Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Canadian and United States securities laws, including the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue." These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to our ability to successfully maintain effective internal controls over financial reporting; our ability to implement our business strategy, manage the growth in our business, and integrate acquired businesses; the risk of litigation and investigations, and liability claims for damages and other expenses not covered by insurance; the risk that payments from third-party payers, including government healthcare programs, may decrease or not increase as costs increase; adverse developments affecting the medical practices of our physician limited partners; our ability to maintain favorable relations with our physician limited partners; our ability to grow revenues by increasing case and procedure volume while maintaining profitability at the Nobilis facilities; failure to timely or accurately bill for services; our ability to compete for physician partners, patients and strategic relationships; the risk of changes in patient volume and patient mix; the risk that laws and regulations that regulate payments for medical services made by government healthcare programs could cause our revenues to decrease; the risk that contracts are cancelled or not renewed or that we are not able to enter into additional contracts under terms that are acceptable to us; and the risk of potential decreases in our reimbursement rates. The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect us in an adverse manner.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. Subject to a mandatory requirements of applicable law, we disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed by March 16, 2017, as updated by other filings with the Securities and Exchange Commission.

Contact:
Tuan Tran
Vice President, Investor Relations
ttran@nobilishealth.com
713-355-8614

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nobilis-health-announces-completion-of-acquisition-of-hamilton-vein-center-300422871.html

SOURCE Nobilis Health Corp.

Nachrichten zu Emdeon Corp.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Emdeon Corp.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!